Argenx Se ARGX.BR

Argenx SE is a European clinical-stage biotechnology company based in Breda, The Netherlands. It serves an international customer base via offices in Belgium, the US, and Japan. Founded in 2008, the firm is involved in the development of life-changing therapeutic treatments aimed at patients with a range of illnesses and conditions, including acute myeloid leukaemia, severe autoimmunity, and chronic inflammatory demyelinating polyneuropathy (CIDP).

The firm has several projects in the pipeline at the pre-clinical phase and at all clinical phases, with a focus on discovering and developing life-changing immunology solutions for patients living with autoimmune diseases. It is involved in academic collaborations with several prestigious institutions, including Bern University, UCL, and Ludwig Cancer Research. Argenx SE has also created an antibody innovation ecosystem, allowing scientists and antibody engineers to work together on vital and innovative antibody research.

The company is listed on the EN Brussels, where it trades under the stock ticker ARGX.BR. In December 2021, Argenx announced it had received approval from the US Food and Drug Administration for its product VYVGART, developed for the treatment of generalised myasthenia gravis (gMG) in adult patients.

Stay up to date on the value of Argenx SE by adding ARGX.BR stock to your eToro watchlist.